Kory James Wentworth sold $19k of TRDA
Chief Financial Officer at Entrada Therapeutics, Inc.. 1,784 shares at an average of $10.67, traded Mar 17, 2025, filed Mar 19, 2025.
Score components
- +22RoleCFO
- 0Trade size$19k at market
- 0Share of holdings soldSold 1.6% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -24.4%, 3m -34.6%, 6m -52.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001689375-25-000016, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 17, 2025 | SOpen-market sale Common Stock10b5-1 | -1,784 | $10.67 | $19k | 109,536 | Mar 19, 2025 |
Related signals
Other insiders at Entrada Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $1.9M 259,837 shares | -6% | |
| 45Moderate | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $1.9M 259,837 shares | -6% | |
| 40Moderate | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $617k 86,482 shares | -2% | |
| 40Moderate | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $617k 86,482 shares | -2% | |
| 36Weak | TRDAbuy Entrada Therapeutics, Inc. | Bernhardt G Zeiher director | $29k 5,000 shares | - | |
| 6Weak | Entrada Therapeutics, Inc. | Nathan J Dowden President & COO | $230k 15,000 shares | -7% | |
| 29Weak | Entrada Therapeutics, Inc. | Natarajan Sethuraman President, Research & Develop. | $399k 25,907 shares | -11% | |
| 7Weak | Entrada Therapeutics, Inc. | Kory James Wentworth Chief Financial Officer | $32k 2,500 shares | -2% | |
| 20Weak | Entrada Therapeutics, Inc. | Nathan J Dowden President & COO | $196k 15,010 shares | -7% | |
| 27Weak | Entrada Therapeutics, Inc. | Kory James Wentworth Chief Financial Officer | $214k 16,477 shares | -12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.